COVID-19 Disease and Vitamin D : A Mini-Review
Copyright © 2020 Boulkrane, Ilina, Melchakov, Fedotova, Drago, Gozzo, Das, Abd El-Aty and Baranenko..
Novel coronavirus disease (COVID-19) pandemic caused by SARS-CoV-2, for which there is no effective treatment except employing prevention strategies, has already instituted significant number of deaths. In this review, we provide a scientific view on the potential role of vitamin D in SARS-CoV-2 virus/COVID-19 disease. Vitamin D is well-known to play a significant role in maintaining the immune health of an individual. Moreover, it induces antimicrobial peptide expression that can decrease viral replication and regulate the levels of pro-inflammatory/anti-inflammatory cytokines. Therefore, supplementation of vitamin D has the potential to reduce the incidence, severity and the risk of death from pneumonia resulting from the cytokine storm of many viral infections including COVID-19. We suggest that supplementation of subjects at high risk of COVID-19 with vitamin D (1.000 to 3.000 IU) to maintain its optimum serum concentrations may be of significant benefit for both in the prevention and treatment of the COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Frontiers in pharmacology - 11(2020) vom: 28., Seite 604579 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boulkrane, Mohamed Said [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID 19 |
|---|
| Anmerkungen: |
Date Revised 10.11.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fphar.2020.604579 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319549925 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319549925 | ||
| 003 | DE-627 | ||
| 005 | 20231225171705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2020.604579 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1065.xml |
| 035 | |a (DE-627)NLM319549925 | ||
| 035 | |a (NLM)33390994 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boulkrane, Mohamed Said |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 Disease and Vitamin D |b A Mini-Review |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2020 Boulkrane, Ilina, Melchakov, Fedotova, Drago, Gozzo, Das, Abd El-Aty and Baranenko. | ||
| 520 | |a Novel coronavirus disease (COVID-19) pandemic caused by SARS-CoV-2, for which there is no effective treatment except employing prevention strategies, has already instituted significant number of deaths. In this review, we provide a scientific view on the potential role of vitamin D in SARS-CoV-2 virus/COVID-19 disease. Vitamin D is well-known to play a significant role in maintaining the immune health of an individual. Moreover, it induces antimicrobial peptide expression that can decrease viral replication and regulate the levels of pro-inflammatory/anti-inflammatory cytokines. Therefore, supplementation of vitamin D has the potential to reduce the incidence, severity and the risk of death from pneumonia resulting from the cytokine storm of many viral infections including COVID-19. We suggest that supplementation of subjects at high risk of COVID-19 with vitamin D (1.000 to 3.000 IU) to maintain its optimum serum concentrations may be of significant benefit for both in the prevention and treatment of the COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID 19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a respiratory tract infection | |
| 650 | 4 | |a vitamin D3 | |
| 650 | 4 | |a vitamin D3 receptor | |
| 700 | 1 | |a Ilina, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Melchakov, Roman |e verfasserin |4 aut | |
| 700 | 1 | |a Fedotova, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Drago, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Gozzo, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Undurti Narasimha |e verfasserin |4 aut | |
| 700 | 1 | |a Abd El-Aty, A M |e verfasserin |4 aut | |
| 700 | 1 | |a Baranenko, Denis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in pharmacology |d 2010 |g 11(2020) vom: 28., Seite 604579 |w (DE-627)NLM208568891 |x 1663-9812 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g day:28 |g pages:604579 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fphar.2020.604579 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |b 28 |h 604579 | ||